Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

<h4>Background</h4>Adalimumab is a fully human, monoclonal antibody against tumor necrosis factor that is approved in Western countries for the treatment of moderately to severely active ulcerative colitis (UC).<h4>Methods</h4>This 52-week, phase 2/3, randomized, double-blind study evaluated adalimu... View More